6.10Open6.10Pre Close0 Volume2 Open Interest22.00Strike Price0.00Turnover160.58%IV22.55%PremiumSep 20, 2024Expiry Date1.47Intrinsic Value100Multiplier24DDays to Expiry4.63Extrinsic Value100Contract SizeAmericanOptions Type-0.4803Delta0.0466Gamma4.83Leverage Ratio-0.0683Theta-0.0084Rho-2.32Eff Leverage0.0212Vega
Boxman : Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company’s Cardiac Surgery System to successfully treat two patients with atrial fibrillation at St. Antonius Hospital, Nieuwegein, The Netherlands. Dr. Van Putte was joined by colleagues and Pulse Biosciences’ Chief Medical Officer, Cardiac Surgery, Dr. Gan Dunnington and Chief Science Officer, Cardiac Surgery, Dr. Niv Ad during the concomitant procedure. The first-in-human feasibility study is a multicenter study of up to 30 patients that will include an endocardial catheter-based remapping to confirm chronic isolation at approximately three months post treatment